临床试验/NCT00793052

NCT00793052Unknown不适用

Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery: A Prospective, Double-Blind Study

Tel-Aviv Sourasky Medical Center0 个研究点目标入组 80 人开始时间: 2008年11月最近更新: 2008年11月19日

适应症

干预措施

试验速览

阶段: 不适用
发起方: Tel-Aviv Sourasky Medical Center
入组人数: 80
主要终点: PAIN- By VAS graded from 1-10 TRISMUS- By MAX mouth opening from the first incisors adages POST OPERATIVE SWELLing - By measurement the distance between the Right and LEFT ear's tragus

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to determine whether Etodalac, Etoricoxib and Dexamethasone are effective for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Patients who are refered for third molar extraction to our center
•Must be able to swallow tablets

排除标准

•Diabetes mellitus
•Thyroid diseases
•Cardiovascular diseases
•renal diseases
•hepatic diseases
•respiratory system diseases
•adrenal diseases
•Allergy to Etodalac, Etoricoxib or Dexamethasone
•Gastric ulcers
•psychiatric diseases
•Pregnant or breast feeding womans

研究组 & 干预措施

A

Experimental

干预措施: Etodalac, Etoricoxib and Dexamethasone (Drug)

结局指标

主要结局

PAIN- By VAS graded from 1-10 TRISMUS- By MAX mouth opening from the first incisors adages POST OPERATIVE SWELLing - By measurement the distance between the Right and LEFT ear's tragus

时间窗: 1 week

次要结局

未报告次要终点

研究者

发起方

Tel-Aviv Sourasky Medical Center

申办方类型

Other Gov

相似试验

已完成

2 期

Dexamethasone and Etoricoxib for Pain Prevention Following Periodontal SurgeryPain Control

NCT00970112Universidade Estadual de Ponta Grossa20

已完成

4 期

Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar SurgerySurgical WoundPost Operative Pain

NCT05791721University of Belgrade90

已完成

2 期

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local TreatmentAdenocarcinoma of the ProstateProstate Cancer

NCT00165399Dana-Farber Cancer Institute62

已完成

2 期

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancer

NCT00356122Sanofi53

进行中（未招募）

2 期

Premedication to Reduce Amivantamab Associated Infusion Related ReactionsCarcinoma, Non-Small-Cell Lung

NCT05663866Janssen Research & Development, LLC68